GLENMARK LIFE SCIENCES Financial Statement Analysis
|
||
The Revenues of GLENMARK LIFE SCIENCES have increased by 1.79% YoY .
The Earnings Per Share (EPS) of GLENMARK LIFE SCIENCES has increased by 11.53 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
GLENMARK LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 543322|NSE : GLS]
Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹2,161 Cr | ₹2,123 Cr | ₹1,885 Cr | ₹1,537 Cr | ₹886 Cr |
Expenses | ₹1,519 Cr | ₹1,507 Cr | ₹1,294 Cr | ₹1,065 Cr | ₹639 Cr |
Operating Profit (Excl OI) | ₹642 Cr | ₹616 Cr | ₹591 Cr | ₹472 Cr | ₹247 Cr |
Other Income | ₹29 Cr | ₹15 Cr | ₹0.81 Cr | ₹12 Cr | ₹0.99 Cr |
Interest | ₹0.55 Cr | ₹28 Cr | ₹88 Cr | ₹34 Cr | ₹0.61 Cr |
Depreciation | ₹42 Cr | ₹38 Cr | ₹33 Cr | ₹29 Cr | ₹19 Cr |
Profit Before Tax | ₹629 Cr | ₹565 Cr | ₹471 Cr | ₹421 Cr | ₹228 Cr |
Profit After Tax | ₹467 Cr | ₹419 Cr | ₹352 Cr | ₹313 Cr | ₹196 Cr |
Consolidated Net Profit | ₹467 Cr | ₹419 Cr | ₹352 Cr | ₹313 Cr | ₹196 Cr |
Earnings Per Share (Rs) | ₹38.11 | ₹34.17 | ₹358.76 | ₹1,597.44 | ₹997.92 |
PAT Margin (%) | 21.49 | 19.70 | 18.60 | 20.34 | 22.07 |
ROE(%) | 22.33 | 29.87 | 60.91 | 127.84 | 451.05 |
ROCE(%) | 30.01 | 42.24 | 96.75 | 185.60 | 527.74 |
Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
Market Cap | : | ₹ 9,789.0 Cr |
Revenue (TTM) | : | ₹ 2,367.9 Cr |
Net Profit(TTM) | : | ₹ 519.3 Cr |
EPS (TTM) | : | ₹ 42.4 |
P/E (TTM) | : | 18.9 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK LIFE SCIENCES | 4.3% | -13.3% | 82.6% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
GLENMARK LIFE SCIENCES Revenues
[BOM: 543322|NSE : GLS]
Y-o-Y | 1.79 % |
5 Yr CAGR | 24.96 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹2,161 Cr | 1.79 | |
Mar2022 | ₹2,123 Cr | 12.63 | |
Mar2021 | ₹1,885 Cr | 22.63 | |
Mar2020 | ₹1,537 Cr | 73.43 | |
Mar2019 | ₹886 Cr | - |
GLENMARK LIFE SCIENCES Operating Profit
[BOM: 543322|NSE : GLS]
Y-o-Y | 4.26 % |
5 Yr CAGR | 26.96 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹642 Cr | 4.26 | |
Mar2022 | ₹616 Cr | 4.23 | |
Mar2021 | ₹591 Cr | 25.24 | |
Mar2020 | ₹472 Cr | 90.94 | |
Mar2019 | ₹247 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 2.41 % |
5 Yr CAGR | 1.61 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 29.72% | 2.41 | |
Mar2022 | 29.02% | -7.43 | |
Mar2021 | 31.35% | 2.12 | |
Mar2020 | 30.7% | 10.11 | |
Mar2019 | 27.88% | - |
GLENMARK LIFE SCIENCES Profit After Tax
[BOM: 543322|NSE : GLS]
Y-o-Y | 11.52 % |
5 Yr CAGR | 24.30 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹467 Cr | 11.52 | |
Mar2022 | ₹419 Cr | 19.10 | |
Mar2021 | ₹352 Cr | 12.29 | |
Mar2020 | ₹313 Cr | 60.08 | |
Mar2019 | ₹196 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 9.09 % |
5 Yr CAGR | -0.66 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 21.49 % | 9.09 | |
Mar2022 | 19.7 % | 5.91 | |
Mar2021 | 18.6 % | -8.55 | |
Mar2020 | 20.34 % | -7.84 | |
Mar2019 | 22.07 % | - |
GLENMARK LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 543322|NSE : GLS]
Y-o-Y | 11.53 % |
5 Yr CAGR | -55.79 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹38 | 11.53 | |
Mar2022 | ₹34 | -90.48 | |
Mar2021 | ₹359 | -77.54 | |
Mar2020 | ₹1,597 | 60.08 | |
Mar2019 | ₹998 | - |
GLENMARK LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 543322|NSE : GLS]
Y-o-Y | -28.95 % |
5 Yr CAGR | -51.17 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 30.01% | -28.95 | |
Mar2022 | 42.24% | -56.34 | |
Mar2021 | 96.75% | -47.87 | |
Mar2020 | 185.6% | -64.83 | |
Mar2019 | 527.74% | - |
GLENMARK LIFE SCIENCES Share Price vs Sensex
Current Share Price | : | ₹799.1 |
Current MarketCap | : | ₹ 9,789.0 Cr |
Updated EOD on | : | Apr 18,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK LIFE SCIENCES | 4.3% |
-13.3% |
82.6% |
SENSEX | -2.9% |
-0.4% |
20% |
GLENMARK LIFE SCIENCES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | -1.1% | 11.8% | 62% |
S&P BSE MIDSMALLCAP | -1.2% | 9.4% | 62.3% |
S&P BSE ALLCAP | -2.2% | 3.9% | 37% |
S&P BSE HEALTHCARE | -3.1% | 2.5% | 51.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | -0.7% | 12.7% | 67.3% |
NIFTY MID SMALL400 | -1.2% | 9.2% | 59.9% |
NIFTY500 MULTICAP 50:25:25 | -1.8% | 5.7% | 44.8% |
NIFTY 500 | -2.2% | 3.5% | 36% |
You may also like the below Video Courses
FAQ about GLENMARK LIFE SCIENCES Financials
How the annual revenues of GLENMARK LIFE SCIENCES have changed ?
The Revenues of GLENMARK LIFE SCIENCES have increased by 1.79% YoY .
How the Earnings per Share (EPS) of GLENMARK LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of GLENMARK LIFE SCIENCES has increased by 11.53 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs